Overview
Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa). Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).
Indication
For use/treatment in osteoporosis.
Associated Conditions
- Hypocalcemia
- Hypoparathyroidism
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/05/24 | Phase 3 | Recruiting | Visen Pharmaceuticals (Shanghai) Co., Ltd. | ||
2021/11/30 | Phase 1 | Completed | |||
2019/03/18 | Phase 3 | Withdrawn | |||
2017/05/12 | Phase 1 | Completed | |||
2016/09/22 | Phase 4 | Completed | |||
2016/05/25 | Phase 1 | Completed | |||
2011/12/29 | Phase 4 | Completed | |||
2011/11/08 | Phase 3 | Completed | |||
2011/10/19 | Phase 3 | Completed | |||
2011/04/11 | Phase 1 | Withdrawn |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals America, Inc. | 68875-0202 | SUBCUTANEOUS | 25 ug in 0.08 mL | 2/28/2023 | |
| Takeda Pharmaceuticals America, Inc. | 68875-0204 | SUBCUTANEOUS | 75 ug in 0.08 mL | 2/28/2023 | |
| Takeda Pharmaceuticals America, Inc. | 68875-0205 | SUBCUTANEOUS | 100 ug in 0.08 mL | 2/28/2023 | |
| Takeda Pharmaceuticals America, Inc. | 68875-0203 | SUBCUTANEOUS | 50 ug in 0.08 mL | 2/28/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 4/24/2017 | ||
Authorised | 4/24/2017 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| PARATHYROIDINUM | seroyal international inc. | 02235032 | Granules
,
Tablet
,
Drops
,
Pellet
,
Liquid
,
Globules - Oral | 8 X | 4/6/1998 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.